Endocrinology

Help Shape the Future of Denosumab Treatment

As biosimilars enter the denosumab landscape, your perspective as a healthcare provider is critical in understanding what factors influence treatment decisions. This brief survey explores your views on reimbursement considerations, coding challenges, switching comfort, and drivers of biosimilar choice. As a thank you, by completing the survey, you’ll be entered into a drawing for a chance to win a $200 gift card.

Take the survey now and make your voice heard

Latest News

Real-World Study: Semaglutide Lowers Cardiovascular Risk More Than Tirzepatide in Adults With Obesity and CVD / Image credit: ©Corona Borealis/AdobeStock
Real-World Study: Semaglutide Lowers Cardiovascular Risk More Than Tirzepatide in Adults With Obesity and CVD

September 2nd 2025

At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.

More Than One-Third of Middle-Aged Adults with Diabetes Prescribed GLP-1 RAs: Daily Dose / image credit: ©New Africa/AdobeStock
More Than One-Third of Middle-Aged Adults with Diabetes Prescribed GLP-1 RAs: Daily Dose

September 1st 2025

Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial
Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial

August 26th 2025

What Do Individuals With Obesity Want in am "Ideal" Primary Care Visit? image credit ©Coloures-Pic/stock.adobe.com
What Do Individuals With Obesity Want in an "Ideal" Primary Care Visit?

August 26th 2025

FDA Clears First Over-The-Counter CGM for Weight Management From Signos / image credit ©lukszczepanski/stock.adobe.com
Signos Wins Clearance for First Over-The-Counter CGM for Weight Management

August 25th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.